Design, synthesis and evaluation of the Brigatinib analogues as potent inhibitors against tertiary EGFR mutants (EGFRdel19/T790M/C797S and EGFRL858R/T790M/C797S)
作者:Haotian Fang、Yingming Wu、Qitao Xiao、Dongbo He、Tongrui Zhou、Wenzhong Liu、Chun-Hao Yang、Yuli Xie
DOI:10.1016/j.bmcl.2022.128729
日期:2022.9
targeting these mutants. In this study, we designed and synthesized a series of novel 4th generation EGFR inhibitors based on scaffold of Brigatinib. After extensive SAR studies, compound 23, the most promising candidate, exhibited strong biochemical potencies against EGFRdel19/T790M/C797S, EGFRL858R/T790M/C797S and other clinically relevant EGFR mutants while sparing wild type EGFR. In cellular assays
尽管表皮生长因子受体酪氨酸激酶抑制剂 (EGFR-TKI) 对 EGFR 突变的非小细胞肺癌患者的临床疗效令人鼓舞,但仍有相当多的患者在服用 EGFR-TKI 后会产生耐药性并最终出现疾病进展一段时间。EGFR del19/T790M/C797S和 EGFR L858R/T790M/C797S是在奥希替尼耐药肿瘤中发现的两种最常见的三级 EGFR 突变体,目前尚无临床批准的针对这些突变体的治疗方法。在本研究中,我们设计并合成了一系列基于布加替尼支架的新型第四代EGFR抑制剂。经过广泛的 SAR 研究,化合物23最有希望的候选药物对 EGFR del19/T790M/C797S、EGFR L858R/T790M/C797S和其他临床相关 EGFR 突变体表现出强大的生化效力,同时保留了野生型 EGFR。在细胞试验中,化合物23有效抑制 BaF3 EGFR del19/T790M/C797S和